Pacira BioSciences, Inc. (PCRX)
 NASDAQ: PCRX · Real-Time Price · USD
 21.27
 +0.26 (1.24%)
  At close: Oct 30, 2025, 4:00 PM EDT
21.99
 +0.72 (3.39%)
  Pre-market: Oct 31, 2025, 5:56 AM EDT
Pacira BioSciences Revenue
Pacira BioSciences had revenue of $181.10M in the quarter ending June 30, 2025, with 1.73% growth. This brings the company's revenue in the last twelve months to $705.85M, up 2.25% year-over-year. In the year 2024, Pacira BioSciences had annual revenue of $700.97M with 3.85% growth.
Revenue (ttm) 
 $705.85M
Revenue Growth 
 +2.25%
P/S Ratio 
 1.39
Revenue / Employee 
 $893,478
Employees 
 790
Market Cap 
955.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 700.97M | 25.99M | 3.85% | 
| Dec 31, 2023 | 674.98M | 8.16M | 1.22% | 
| Dec 31, 2022 | 666.82M | 125.29M | 23.14% | 
| Dec 31, 2021 | 541.53M | 111.89M | 26.04% | 
| Dec 31, 2020 | 429.65M | 8.62M | 2.05% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 63.62B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Eli Lilly and Company | 53.26B | 
| Novo Nordisk | 49.11B | 
PCRX News
- 1 day ago - Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025 - GlobeNewsWire
- 4 days ago - Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL® - GlobeNewsWire
- 8 days ago - Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL® - GlobeNewsWire
- 9 days ago - Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL® - GlobeNewsWire
- 10 days ago - Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy - GlobeNewsWire
- 4 weeks ago - Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Pacira BioSciences, Inc. (PCRX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Pacira BioSciences Reports Second Quarter 2025 Financial Results - GlobeNewsWire